China Nuclear Imaging Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The China Nuclear Imaging Market is segmented by Product (Equipment, Radioisotope, and PET Radioisotopes) and Application.

Market Snapshot

CAGR
Study Period: 2018 - 2026
Base Year: 2020
CAGR: 9.45 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Chinese nuclear imaging market is expected to grow with a CAGR of 9.45% during the forecast period.

  • Recent years have observed significant growth in the application of nuclear medicine and imaging. The rising prevalence of bone diseases and cancer in China, along with the technological advancements in the field of diagnostics, is expected to drive the growth of the market over the forecast period.
  • Cancer burden and mortality are high in China. As per the latest 2018 report published by the WHO, 4,285,033 new cancer cases, including both the sexes and all ages, were registered in China, whereas the number of deaths was reported to be 2,865,174. Government support, in terms of funding, also contributes to the growth of the radiopharmaceuticals market in China.
  • However, there are certain factors that are hindering the growth of the market, such as the shorter half-life of radiopharmaceuticals and high cost of the techniques.

Scope of the Report

As per the scope of the report, nuclear medicine imaging procedures are non-invasive and, with the exception of intravenous injections, are usually painless medical tests that help physicians diagnose and evaluate medical conditions. These imaging scans use radioactive materials called radiopharmaceuticals or radiotracers.

By Product
By Equipment
By Radioisotope
By Diagnostic Technology
SPECT Radioisotopes
Technetium-99m (TC-99m)
Thallium-201 (TI-201)
Gallium (Ga-67)
Iodine (I-123)
Other SPECT Radioisotopes
PET Radioisotopes
Fluorine-18 (F-18)
Rubidium-82 (RB-82)
Other PET Radioisotopes
By Application
SPECT Applications
Neurology
Cardiology
Thyroid
Other SPECT Applications
PET Applications
Oncology
Cardiology
Neurology
Other PET Applications

Report scope can be customized per your requirements. Click here.

Key Market Trends

The PET Equipment Segment is Expected to Grow with a Significant CAGR

The PET equipment segment covers stand-alone PET, hybrid PET/CT, hybrid PET/MRI, PET infusion systems, and cyclotrons used to produce short-lived radioisotopes on site. A positron emission tomography (PET) scan is an imaging test that allows the doctor to detect diseases in one’s body. A PET scan is majorly used in oncology applications. The China Society of Nuclear Medicine was established in 1980. Since then, nuclear medicine has been developed rapidly in China. According to the Chinese Society of Nuclear Medicine, there were a total of 306 PET scanners in 2017. Additionally, there are more than 900 departments of nuclear medicine in China that are actively running, and about more than one million patients receive nuclear medicine imaging examinations, per year, across the country. Moreover, with the government’s support, the Chinese nuclear imaging market is expected to grow, in the future.

Pet

Competitive Landscape

The market comprises of major market players and these players are moreover focusing on R&D to strengthen their position in the market. The market has been noticing technological developments on a large scale for the past couple of years. Some of the market players are Bayer AG, Bracco Imaging SpA, Canon Inc., Cardinal Health Inc., China Isotope & Radiation Corporation (CIRC), Curium Pharma, GE Healthcare, Global Medical Solutions Ltd, Koninklijke Philips NV, Siemens Healthineers, and Yantai Dongcheng Pharmaceutical Group Co. Ltd.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Cancer and Cardiac Disorders

      2. 4.2.2 Increased Technological Advancements

      3. 4.2.3 Growth in Applications of Nuclear Medicine and Imaging

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of the Techniques

      2. 4.3.2 Short Half-life of Radiopharmaceuticals

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product

      1. 5.1.1 By Equipment

      2. 5.1.2 By Radioisotope

        1. 5.1.2.1 By Diagnostic Technology

          1. 5.1.2.1.1 SPECT Radioisotopes

            1. 5.1.2.1.1.1 Technetium-99m (TC-99m)

            2. 5.1.2.1.1.2 Thallium-201 (TI-201)

            3. 5.1.2.1.1.3 Gallium (Ga-67)

            4. 5.1.2.1.1.4 Iodine (I-123)

            5. 5.1.2.1.1.5 Other SPECT Radioisotopes

          2. 5.1.2.1.2 PET Radioisotopes

            1. 5.1.2.1.2.1 Fluorine-18 (F-18)

            2. 5.1.2.1.2.2 Rubidium-82 (RB-82)

            3. 5.1.2.1.2.3 Other PET Radioisotopes

    2. 5.2 By Application

      1. 5.2.1 SPECT Applications

        1. 5.2.1.1 Neurology

        2. 5.2.1.2 Cardiology

        3. 5.2.1.3 Thyroid

        4. 5.2.1.4 Other SPECT Applications

      2. 5.2.2 PET Applications

        1. 5.2.2.1 Oncology

        2. 5.2.2.2 Cardiology

        3. 5.2.2.3 Neurology

        4. 5.2.2.4 Other PET Applications

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bayer AG

      2. 6.1.2 Bracco Imaging SpA

      3. 6.1.3 Canon Inc.

      4. 6.1.4 Cardinal Health Inc.

      5. 6.1.5 China Isotope & Radiation Corporation (CIRC)

      6. 6.1.6 Curium Pharma

      7. 6.1.7 GE Healthcare

      8. 6.1.8 Global Medical Solutions Ltd

      9. 6.1.9 Koninklijke Philips NV

      10. 6.1.10 Siemens Healthineers

      11. 6.1.11 Yantai Dongcheng Pharmaceutical Group Co. Ltd

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The China Nuclear Imaging Market market is studied from 2018 - 2026.

The China Nuclear Imaging Market is growing at a CAGR of 9.45% over the next 5 years.

Yantai Dongcheng Pharmaceutical Group Co. Ltd, Bracco Imaging SpA, Canon Inc., China Isotope & Radiation Corporation (CIRC), GE Healthcare are the major companies operating in China Nuclear Imaging Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!